Intratumoral and peritumoral ultrasound radiomics analysis for predicting HER2-low expression in HER2-negative breast cancer patients: a retrospective analysis of dual-central study

ObjectiveThis study aims to explore whether intratumoral and peritumoral ultrasound radiomics of ultrasound images can predict the low expression status of human epidermal growth factor receptor 2 (HER2) in HER2-negative breast cancer patients.MethodsHER2-negative breast cancer patients were recruited retrospectively and randomly divided into a training cohort (n = 303) and a test cohort (n = 130) at a ratio of 7:3. The region of interest within the breast ultrasound image was designated as the intratumoral region, and expansions of 3 mm, 5 mm, and 8 mm from this region were considered as the peritumoral regions for the extraction of ultrasound radiomic features. Feature extraction and selection were performed, and radiomics scores (Rad-score) were obtained in four ultrasound radiomics scenarios: intratumoral only, intratumoral + peritumoral 3 mm, intratumoral + peritumoral 5 mm, and intratumoral + peritumoral 8 mm. An optimal combined nomogram radiomic model incorporating clinical features was established and validated. Subsequently, the diagnostic performance of the radiomic models was evaluated.ResultsThe results indicated that the intratumoral + peritumoral (5 mm) ultrasound radiomics exhibited the excellent diagnostic performance in evaluated the HER2 low expression. The nomogram combining intratumoral + peritumoral (5 mm) and clinical features showed superior diagnostic performance, achieving an area under the curve (AUC) of 0.911 and 0.869 in the training and test cohorts, respectively.ConclusionThe combination of intratumoral + peritumoral (5 mm) ultrasound radiomics and clinical features possesses the capability to accurately predict the low-expression status of HER2 in HER2-negative breast cancer patients.